NCT06906627 Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
| NCT ID | NCT06906627 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | Chronic Kidney Disease(CKD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 750 participants |
| Start Date | 2025-10-28 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 750 participants in total. It began in 2025-10-28 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Eligibility Criteria
Screening Program- Inclusion Criteria: * Adults with type 2 diabetes (T2D) * Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP). * Lack of estimated glomerular filtration rate (eGFR) and/or urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR Exclusion Criteria: • Chronic kidney disease (CKD) diagnosis
Contact & Investigator
Neha Pagidipati, MD
PRINCIPAL INVESTIGATOR
Duke University
Frequently Asked Questions
Who can join the NCT06906627 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Disease(CKD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06906627 currently recruiting?
Yes, NCT06906627 is actively recruiting participants. Contact the research team at gretchen.sanders@duke.edu for enrollment information.
Where is the NCT06906627 trial being conducted?
This trial is being conducted at Birmingham, United States, St. Petersburg, United States, Ann Arbor, United States, Duluth, United States and 3 additional locations.
Who is sponsoring the NCT06906627 clinical trial?
NCT06906627 is sponsored by Duke University. The principal investigator is Neha Pagidipati, MD at Duke University. The trial plans to enroll 750 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.